When was Mabtech founded?

Mabtech was founded in 1986 and raised its 1st funding round 30 years after it was founded.

Where is Mabtech located?

Mabtech is headquartered in Nacka, Sweden.

How many employees does Mabtech have?

As of Jul 01, 2024, the latest employee count at Mabtech is 11 - 50.

Is Mabtech a funded company?

Mabtech is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 01, 2016.

When was the latest funding round of Mabtech?

Mabtech's latest funding was a $***** Grant (prize money) round on Oct 01, 2020, with participation from 1 investor.

Where does Mabtech rank among its competitors?

Mabtech ranks 8th amongst 272 active competitors, of which 16 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Y-Biologics, which secured $25.2M in Aug, 2025.

Who are the top competitors of Mabtech?

Mabtech's top competitors include Sino Biological, GenScript and Y-Biologics. Among them, Y-Biologics secured the most recent funding round in August, 2025.

Mabtech - 2026 Company Profile, Team, Funding & Competitors

Mabtech is an acquired company based in Nacka (Sweden), founded in 1986. It operates as a Develops antibodies and ELISA kits. Mabtech has raised an undisclosed amount in funding from Merieux Equity Partners. The company has 272 active competitors, including 16 funded and 39 that have exited. Its top competitors include companies like Sino Biological, GenScript and Y-Biologics.

Company Details

Mabtech develops antibodies and antibody-related kits and reagents. The product line of the company includes Antibodies, ELISA Kits, ELISpot Kits, and FluoroSpot Kits for various applications. It collaborates with research institutes to run R&D programs.

Website: www.mabtech.com/
Social
Email ID: *****@mabtech.com
Phone Number: +46 **********

Key Metrics

Founded Year

1986

Location

Nacka, Sweden

Stage

Acquired

Latest Funding Round

Grant (prize money), Oct 01, 2020, $*****

Investors

Merieux Equity Partners & 2 more

Ranked

8^th among 272 active competitors

Employee Count

11 - 50 as on Jul 01, 2024

Similar Companies

Sino Biological & 329 more

Exit Details

Acquired by EQT (Jan 09, 2024)

View Mabtech's full profile

Mabtech got acquired by EQT on Jan 09, 2024.

Click here to take a look at Mabtech's acquisition in detail

Mabtech has raised funding over 5 rounds. Its first funding round was on Sep 01, 2016. Its latest funding round was a Grant (prize money) round on Oct 01, 2020 for $*****. 1 investor participated in its latest round. Mabtech has 3 institutional investors.

Here is the list of recent funding rounds of Mabtech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2020	5432420	Grant (prize money)	2181727	2570632	1622097	5962426
Nov 26, 2019	4935833	PE	8319272	8760737	1048645	IK Partners
Apr 01, 2018	3111139	Grant (prize money)	5985679	4239353	7991022	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Mabtech's funding rounds and investors

Mabtech's employee count trend

Mabtech has 11 - 50 employees as of Jul 24. Here is Mabtech's employee count trend over the years:

Uncover Mabtech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mabtech include Sino Biological, GenScript and Y-Biologics. Here is the list of Top 10 competitors of Mabtech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	CTS Capital, Qiming Venture Partners & 1 others	64/100
2nd	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	59/100
3rd	Y-Biologics 2007, Daejeon (South Korea), Public	Developer of antibodies for the treatment of multiple diseases	$42.1M	InterVest, IMM Investment & 14 others	56/100
4th	Shanghai OPM Biosciences 2013, Pudong (China), Series B	Antibody culture media and vaccine culture products developer	$14.4M	CPE, China Life Great Health Fund & 5 others	54/100
5th	Allele Biotech 1999, San Diego (United States), Series B	cGMP iPSCs and cell therapy CDMO accelerating regenerative medicine programs	$18M	NIH, HHS & 1 others	52/100
6th	Bio X Cell 1997, Lebanon (United States), Acquired	Provider of antibodies and antibody production services for in vivo use	-	-	50/100
7th	ITBMed 2016, Stockholm (Sweden), Series A	Developer of monoclonal antibodies to prevent transplant rejections	$87M	Yonjin Capital, 3E Bioventures Capital & 2 others	50/100
8th	Mabtech 1986, Nacka (Sweden), Acquired	Develops antibodies and ELISA kits	-	IK Partners, Merieux Equity Partners & 1 others	50/100
9th	Pixelgen Technolgies 2020, Stockholm (Sweden), Series A	Developer of ground-breaking technologies for biomedical research and diagnostics	$6M	Industrifonden, Navigare Ventures & 1 others	50/100
10th	Immuno-Biological Laboratories 1982, Fujioka (Japan), Public	Manufacture antibodies	-	Japan Asia Investment, Whiz Partners & 3 others	49/100